Oncology /Immuno-oncology Platform
Non-Human Primates Platform
Inflammation/Autoimmune Diseases Model
Metabolic/Liver/Cardiovascular Diseases Model
There have been no specific therapeutic drugs for idiopathic pulmonary fibrosis. This lack of effective therapies can be attributed to the fact that previous animal models of idiopathic pulmonary fibrosis have not effectively replicated the pathological manifestations of the disease. Therefore, it is very important that a better animal model of pulmonary fibrosis is established to study the pathogenesis of human idiopathic pulmonary fibrosis and to develop effective therapeutic drugs. To establish a mouse model of pulmonary fibrosis which is more consistent with the pathological characteristics of human idiopathic pulmonary fibrosis, we developed a bleomycin induced pulmonary fibrosis model in mice.
Pulmonary fibrosis is an end-stage change of pulmonary diseases characterized by fibroblast proliferation and a large number of extracellular matrix aggregation accompanied by inflammation and tissue damage. Pulmonary fibrosis seriously affects respiratory function. The clinical manifestations are dry cough and progressive dyspnea. Bleomycin is a broad-spectrum anti-tumor drug. It is one of the most commonly used drugs in animal models of pulmonary fibrosis because of its low activity of amidase and low inactivation of bleomycin hydrolysis.
Animal: C57BL/6 Mice, Male, 22-25.
Methods: Bleomycin solution is given to mice via intratracheal instillation.
Endpoint: Body Weight and Survival Rate
· Intratracheal administration of bleomycin induced pulmonary fibrosis on the basis of histological examination displaying fibrotic thickening and epithelial hyperplasia.
· Hydroxyproline in lungs with pulmonary fibrosis was increased significantly which is consistent with fibrosis characterization.